
 
 
 
 
 
 
 
 
   
 1. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2. 
 
     
 2. The nucleic acid of  claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2. 
 
     
 3. The nucleic acid of  claim 1 , wherein the nucleic acid comprises SEQ ID NO:1. 
 
     
 4. A transfonnant identified by international deposit accession No.FERM BP-5725. 
 
     
 5. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added; wherein,
 (a) the polypeptide comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region, 
 (b) the polypeptide comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and 
 (c) an antibody reactive with the polypeptide induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3. 
 
 
     
 6. The nucleic acid of  claim 5 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NQ:2 in which one to ten amino acids are substituted, deleted or added. 
 
     
 7. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising:
 (a) an extracellular region of the protein set forth in SEQ ED NO:2, or 
 (b) an extracellular region of a protein that consists of the amino acid sequence of SEQ ID NO:2 in which one to ten amino acid residues are substituted, deleted or added; 
 wherein the polypeptide comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) and inhibits the activation of lymphocytes. 
 
 
     
 8. The nucleic acid of  claim 7 , wherein the polypeptide consists of:
 (a) an extracellular region of the protein set forth in SEQ ID NO:2, or 
 (b) an extracellular region of a protein that consists of the amino acid sequence of SEQ ID NO:2 in which one to ten amino acid residues are substituted, deleted or added. 
 
 
     
 9. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising amino acid residues 1–140 of SEQ ID NO:2. 
 
     
 10. The nucleic acid of  claim 9 , wherein the polypeptide consists of amino acid residues 1–140 of SEQ ID NO:2. 
 
     
 11. A nucleic acid comprising a nucleotide sequence that encodes a fusion protein comprising:
 (a) an extracellular region of (i) the polypeptide set forth in SEQ ED NO:2, or (ii) a polypeptide that consists of the amino acid sequence of SEQ ID NO:2 in which one to ten amino acid residues are substituted, deleted or added; and 
 (b) a portion of a constant region of a human inimunoglobulin heavy chain; 
 wherein the fusion protein comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) and inhibits the activation of lymphocytes. 
 
 
     
 12. The nucleic acid of  claim 11 , wherein the fusion protein consists of:
 (a) an extracellular region of (i) the polypeptide set forth in SEQ ID NO:2, or (ii) a polypeptide that consists of the amino acid sequence of SEQ ID NO:2 in which one to ten amino acid residues are substituted, deleted or added; and 
 (b) a portion of a constant region of a human immunoglobulin heavy chain. 
 
 
     
 13. The nucleic acid of  claim 11 , wherein the extracellular region is amino acid residues 1–140 of SEQ ID NO:2. 
 
     
 14. The nucleic acid of  claim 12 , wherein the extracellular region is amino acid residues 1–140 of SEQ ID NO:2. 
 
     
 15. The nucleic acid of  claim 11 , wherein the portion of the constant region of a human inimunoglobulin heavy chain consists of the hinge region, CH2 domain, and CH3 domain of human IgG heavy chain. 
 
     
 16. The nucleic acid of  claim 12 , wherein the portion of the constant region of a human immunoglobulin heavy chain consists of the hinge region, CH2 domain, and CH3 domain of human IgG heavy chain. 
 
     
 17. The nucleic acid of  claim 13 , wherein the portion of the constant region of a human immunoglobulin heavy chain consists of the hinge region, CH2 domain, and CH3 domain of human IgG heavy chain. 
 
     
 18. The nucleic acid of  claim 14 , wherein the portion of the constant region of a human immunoglobulin heavy chain consists of the hinge region, CH2 domain, and CH3 domain of human IgG heavy chain. 
 
     
 19. An isolated nucleic acid comprising the cDNA insert of plasmid pBSh41 of the transformant identified by international deposit accession number FERM BP-5725. 
 
     
 20. An isolated nucleic acid comprising a nucleotide sequence which encodes a polypeptide comprising an amino acid sequence encoded by the cDNA insert of plasmid pBSh41 of the transformant identified by international deposit accession number FERM BP-5725. 
 
     
 21. A vector comprising the nucleic acid of  claim 1 . 
 
     
 22. A vector comprising the nucleic acid of  claim 2 . 
 
     
 23. A vector comprising the nucleic acid of  claim 3 . 
 
     
 24. A vector comprising the nucleic acid of  claim 5 . 
 
     
 25. A vector comprising the nucleic acid of  claim 6 . 
 
     
 26. A vector comprising the nucleic acid of  claim 7 . 
 
     
 27. A vector comprising the nucleic acid of  claim 8 . 
 
     
 28. A vector comprising the nucleic acid of  claim 9 . 
 
     
 29. A vector comprising the nucleic acid of  claim 10 . 
 
     
 30. A vector comprising the nucleic acid of  claim 11 . 
 
     
 31. A vector comprising the nucleic acid of  claim 12 . 
 
     
 32. A vector comprising the nucleic acid of  claim 13 . 
 
     
 33. A vector comprising the nucleic acid of  claim 14 . 
 
     
 34. A vector comprising the nucleic acid of  claim 15 . 
 
     
 35. A vector comprising the nucleic acid of  claim 16 . 
 
     
 36. A vector comprising the nucleic acid of  claim 17 . 
 
     
 37. A vector comprising the nucleic acid of  claim 18 . 
 
     
 38. A vector comprising the nucleic acid of  claim 19 . 
 
     
 39. A vector comprising the nucleic acid of  claim 20 . 
 
     
 40. A host cell comprising the vector of  claim 21 . 
 
     
 41. A host cell comprising the vector of  claim 22 . 
 
     
 42. A host cell comprising the vector of  claim 23 . 
 
     
 43. A host cell comprising the vector of  claim 24 . 
 
     
 44. A host cell comprising the vector of  claim 25 . 
 
     
 45. A host cell comprising the vector of  claim 26 . 
 
     
 46. A host cell comprising the vector of  claim 27 . 
 
     
 47. A host cell comprising the vector of  claim 28 . 
 
     
 48. A host cell comprising the vector of  claim 29 . 
 
     
 49. A host cell comprising the vector of  claim 30 . 
 
     
 50. A host cell comprising the vector of  claim 31 . 
 
     
 51. A host cell comprising the vector of  claim 32 . 
 
     
 52. A host cell comprising the vector of  claim 33 . 
 
     
 53. A host ccli comprising the vector of  claim 34 . 
 
     
 54. A host cell comprising the vector of  claim 35 . 
 
     
 55. A host cell comprising the vector of  claim 36 . 
 
     
 56. A host cell comprising the vector of  claim 37 . 
 
     
 57. A host cell comprising the vector of  claim 38 . 
 
     
 58. A host cell comprising the vector of  claim 39 . 
 
     
 59. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 40  under conditions in which the polypeptide is produced. 
 
     
 60. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 41  under conditions in which the polypeptide is produced. 
 
     
 61. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 42  under conditions in which the polypeptide is produced. 
 
     
 62. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 43  under conditions in which the polypeptide is produced. 
 
     
 63. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 44  under conditions in which the polypeptide is produced. 
 
     
 64. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 45  under conditions in which the polypeptide is produced. 
 
     
 65. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 46  under conditions in which the polypeptide is produced. 
 
     
 66. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 47  under conditions in which the polypeptide is produced. 
 
     
 67. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 48  under conditions in which the polypeptide is produced. 
 
     
 68. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 49  under conditions in which the polypeptide is produced. 
 
     
 69. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 50  under conditions in which the polypeptide is produced. 
 
     
 70. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 51  under conditions in which the polypeptide is produced. 
 
     
 71. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 52  under conditions in which the polypeptide is produced. 
 
     
 72. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 53  under conditions in which the polypeptide is produced. 
 
     
 73. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 54  under conditions in which the polypeptide is produced. 
 
     
 74. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 55  under conditions in which the polypeptide is produced. 
 
     
 75. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 56  under conditions in which the polypeptide is produced. 
 
     
 76. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 57  under conditions in which the polypeptide is produced. 
 
     
 77. A method for producing a polypeptide, the method comprising culturing the host cell of  claim 58  under conditions in which the polypeptide is produced. 
 
   
 
 
 
 
 
 
 
 
